even at the height of the country's economic crisis novartis was overcharging for drugs according to the greek government it says that left thousands without access to affordable medicine between two thousand and six and twenty fifteen the swiss drug maker allegedly bribed thousands of doctors and civil servants including the former finance minister he is accused of signing documents that unable to tax bill from the boxes to be merged with public sector debt he was you to yourself this was not ladies and gentlemen the statements are entirely fictitious i never signed anything of the sort my nor did i have the authority to do so and i don't think anyone else signed either. explore first weeks now i have asked to be shown the relevant documents with my signatures they simply don't exist. greece's parliament is now investigating about a dozen senior politicians novartis says it's cooperating with the greek authorities while conducting an internal audit the swiss drugmaker has already paid multimillion dollar fines in the u.s. china and south korea to settle corruption cases. dutch force

novartis says it is cooperating with authorities — and is conducting its own investigation.r north america — raj nair — will leave immediately. it says an investigation found his behaviour was inconsistent with ford's code of conduct but it wouldn't say what the inappropriate behaviour involved. what is trending in business... they are talking about the us regulator issuing new guidelines are warning against executives trading shares before announcing security issues. last year, there were reports of such sales. chinese researchers have shown up their design for an aircraft which could travel at more than five times the speed of sound. beijing to new york in just two hours. keep in touch with us and i will see you in just a moment. university lecturers across the uk will go on strike today following a dispute over pensions. it's the start of two weeks of industrial action which will affect millions of students. the union representing academics says as many as 42,000 staff at 61 universities are affected by the changes. elaine dunkley reports. thousands of lectures counselled

but when novartis brought the first version to market it put a price on of $475,000, just for the drug. then the cost of care associated with administering the drug is another half-million dollars and i am not exaggerating. it is a million dollar treatment. we can't keep pricing drugs this way, that we all pay to develop. we have to have a discussion about how we price drugs to maximize accessibility and affordability while maintaining a rich rnd pipeline and reasonable profit for the company. host: circle back to the creates act, this from axios reporting the pharmaceutical industry was able to keep the create tax out of the budget agreement that came out last week. the gist of the create tax make it easier for companies to obtain samples of brand-name products they are trying to copy, an integral step of copying them. senior republican aide says the problem with the create tax, it would be giving away the store to trial lawyers and allow generics to sue for access to product samples. i want to get to respond to that. guest: that senior staffer is confused. trial lawyers can't sue und

even at the height of the country's economic crisis novartis was over charging for drugs according to the greek government it says that left thousands without access to affordable medicine between two thousand and six and twenty fifteen the swiss drug maker allegedly bribed thousands of doctors and civil servants including the former finance minister he is accused of signing documents that unable to tax bill from the vox is to be merged with public sector debt. ladies and gentlemen these statements are entirely facts and never signed anything of the sort mine or did i have the authority to do so and i don't think anyone else signed either. if for fish for weeks now i have asked to be shown the relevant documents with my signatures they simply don't exist. greece's parliament is now investigating about a dozen senior politicians novartis says it's cooperating with the greek authorities while conducting an internal audit the swiss drugmaker has already paid multimillion dollar fines in the u.s. china and south korea to settle corruption cases. a strike by air france on board personnel h

greece's parliament is now investigating about a dozen politicians novartis says it's corporation with the greek authorities while conducting an internal audit the swiss drugmaker has already paid multimillion dollar fines in the us china and south korea to settle corruption cases. such force acute prosecutors some thirsty rejected calls to open a criminal investigation into four major tobacco companies on charges including attempted murder or manslaughter saying such a case would be unlikely to lead to a conviction. in two thousand and sixteen two former smokers in the netherlands fired what they call the road first carmen a complaint seeking a prosecution hospital doctors and other groups later joined the cause but that's prosecutors say they see no prospect of a conviction within current laws. my mental habit occurs people have the choice to buy cigarettes people have the choice to start smoking cigarettes and that means with regards to addiction or serious bodily harm it had not be blamed solely on cigarette manufacturers and couldn't see where the fabric and their decision is a bl

accepted bribes between two thousand and six and two thousand and fifteen from the swiss corporation novartis in order to enable price gouging and increased market access the accused include the current governor of greek central bank and two former prime ministers current prime minister alexis tsipras called the case one of the biggest scandals in the country's modern history under greek law prosecutors must actually refer the cases involving politicians to the parliament which then investigates and decides whether or not to revoke immunity before indictments can occur the u.s. federal bureau of investigation the f.b.i. assisted greek prosecutors and looking for evidence of money laundering this was key to making the case as there is a greek statute of limitations for bribery but not for money laundering. the world will need more than half a million new pilots in less than twenty years according to a study by airline maker boeing demand is expected to increase dramatically by twenty thirty six an estimated six hundred thirty thousand new pilots are going to be needed with more than a quarter

accepted bribes between two thousand and six and two thousand and fifteen from the swiss corporation novartis in order to enable price gouging and increased market access the accused include the current governor of greek central bank and two former prime ministers current from prime minister alexis tsipras called the case one of the biggest scandals in the country's modern history under greek law prosecutors most actually refer the cases involving politicians to the parliament which then investigates and decides whether or not to revoke immunity before indictments can occur the u.s. federal bureau of investigation the f.b.i. assisted greek prosecutors and looking for evidence of money laundering this was tina making the case as there is a greek statute of limitations for bribery but not for money laundering. the world will need more than half a million new pilots in less than twenty years according to a study by airline maker boeing demand is expected increase dramatically by two. twenty thirty six an estimated six hundred thirty thousand new pilots are going to be needed with more than a qua

novartis is down 1%. watch these luxury stocks. let's switch over to the winners.a look at who's on the right side of your screen. as we are ready mentioned, you are going to see total up there because they're going to make noise about giving money back to investors. you see swiss three as a big gainer. zurich insurance up three and a half. i guess it's late enough that they still could be a wash on jamison. some of the banks gaining as well. that's the sector economy paint tickler attention to today. take.et's get a broader europe is lower. strong session yesterday in europe. we were working for a bounce and we got it. good morning. how is the portfolio? >> really because of the equities. we had some stock specific risk and it did not fall as much as market would've hoped. diversifying assets has not really worked. there hasn't been anything rising in this market in the chaos. we feel a little bit lucky over the last few days. matt: do you expect these kinds of scenarios? it would be more unusual to see one short, sharp drop. and then to move on with the bull mark

nestle, novartis, royal dutch shell.spans the gamut from consumer to discretionary to pharma to oil. you see bank in their with hsbc. the biggest names hosting big drops. you very rarely see all 10 of the biggest losers on the stoxx 600 with jobs at 1% or more. today we are looking at 2%, 3%, 4% and even 5% drops. as far as the winning side of the screen, you only got one stock, cap at it elc. plc.tap to -- slight gains, very little gains and every thing else, you can these german, stocks are not open yet. takes longer on a normal day. breadth to the downside. guy: biggest move since june 2016. let's get some take on these markets. this get more analysis to figure out what is going on. mark cudmore joining us. he is a strategist. steven major, joining us from hsbc. mr. cudmore, let's start with you. what you make with this market move? mark: there was more pain to come. the risk aversion, these things don't go in a straight line. it means lower liquidity and the fact that everyone has weaker hands. there are negative wea

novartis, ande this is what russia has delivered. inther dividend increases swiss franc. core earnings-per-share is a ins, the market had penciled 15.53. the guidance they are giving to the market, they're saying they expect low single-digit guidance , stable growth, but they're talking about low single-digit range. back in july, they increase the focus to mid single-digit growth. so there's a bit of a question mark there in terms of the guidance. earnings-per-share is amiss. they are talking about dividends in the future. the big companies that should benefit from the tax reform in the united states, they believe at roche,r, and they're seeing a number of their drugs being hit copycat, they are trying to rebuild that pipeline with things like the hemophilia drug and multiple sclerosis. so it's amiss on earnings-per-share and the guidance for dividends tomorrow is a promise. anna: will return to pharmaceuticals later with key interviews. and nokia, these numbers look to be, fourth quarter looks to be better than estimated. adjusted euros ahead of the estimate. net sales c

the hen novartis brought first version to market it put a for on of $475,000, just the drug.hen the cost of care associated the drug is ering another half million authorize and i'm not exaggerating, it is million dollar treatment. we can't keep pricing drugs this all pay to develop. we have to have a discussion bout how we price drugs to maximize accessibility and affordability while maintaining r&d pipeline and reasonable profit for the company. the creates back to act, this from axios reporting industry was ical able to keep the create tax out that budget agreement came out last week. thegist of the create tax make to asier for companies obtain samples of brand-name products they are trying to an integral step of copying them. the r republican aide says problem with the create tax, it the store ving away to trial lawyers and allow generics to sue for access to product samples. you to respond to that. guest: that senior staffer is confused. -- trial lawyers can't sue samples, only bona fide generic companies who have fab fabrequest with the to manufacture the drug and protoc

>>> this portion of "know your numbers" is brought to you by novartis. >> february is american heartby example. >> here to put us on a heart-healthy path is dr. mehmet oz. >> good morning. >> we got up a little early for you because you thought it would be a good idea if we tested some of our numbers. this is a time when everybody should be checking their stats, right? >> you got to know your numbers. >> there was a recent study that linked age to heart disease. we're obviously very young. you know just for everyone else. >> this is breaking news. and it's pretty important. there's stem cells in our bone marrow, that leads to heart disease. we know people that look perfect that don't have risk factors and still have heart problems. it's not predictive always. but let's focus on the numbers that you can change. you go through the numbers, the most important one to focus on is your blood pressure. i checked your blood pressure. here's your goal. you want to keep your blood pressure 120/80 or below. >> that's the optimal. >> you're going to want to stay 140/90 which is hypertension. and

had been buying in europe >> i did it again this morning i'm getting a 2.58% yield on names like novartis, roche, total, glaxosmithkline, british american tobacco they sell all their products in the united states. >> even at these levels are you looking at u.s. stocks at this point? >> europe right now today, this morning, is a better deal than the u.s. s&p just because those companies sell all their products here in new york city, i can buy them with a fantastic discount. look, chaos is opportunity, i don't know if i hit the bottom the last 45 minutes, talking to my guys over in europe, it's starting maybe to show that bottoming process, which we may see in the next 45 minutes these are wild types but great values >> people are wondering how much damage was done. it was a comprehensive washout the last few days. you lock at how many stocks have broken 10%, 15% below their trend. you see the lopsided volume. you got one of these markets were everything was thrown out, you can kind of pick among them and find if it's so deeply oversold that we at least get a bounce we're back in the days w

accepted bribes between two thousand and six and two thousand and fifteen from the swiss corporation novartis in order to enable price gouging and increased market access the accused include the current governor of greek central bank and two former prime ministers current from prime minister alexis tsipras called the case one of the biggest scandals in the country's modern history under greek law prosecutors most actually refer the cases involving politicians to the parliament which then investigates and decides whether or not to revoke immunity before indictments can occur the u.s. federal bureau of investigation the f.b.i. assisted greek prosecutors and looking for evidence of money laundering this was key to making the case as there is a greek statute of limitations for bribery but not for money laundering. the world will need more than half a million new pilots in less than twenty years according to a study by airline maker boeing demand is expected increased dramatically by to. twenty thirty six an estimated six hundred thirty thousand new pilots are going to be needed with more than a q

novartis, pfizer and united health all belong to and fund n.a.m. if you go on their websites, you'll find them urging people to live healthier, longer lives. so why are they lobbying through n.a.m. to let coal companies make streams look like this? you'll find these companies on their websites touting their commitments to sustainability and to reduce carbon emissions. so why are they lobbying through the national association of manufacturers against climate policies they actually support? the national association of manufacturers rather inexplicably opposes all serious climate action. in particular, it opposes putting a price on carbon emissions. it even funded a debunked study that claimed putting an economy-wide price on carbon would cost millions of jobs. it lobbied for a legislative amendment making it more difficult to begin pricing carbon. but look at n.a.m.'s own member companies who are already pricing carbon emissions. archer daniels midland, cargill, corning, microsoft, and stanley black and decker all apply a price on carbon in their own